NRP2945 as potential therapy for MS progression

[MSUK]

Finanical support given for development of NRP2945 as potential therapy for MS progression

CuroNZ, an Auckland biotechnology start-up company developing treatments for progressive multiple sclerosis, has been awarded funding of US$ 540,000 from the National Multiple Sclerosis Society through Fast Forward to support preclinical studies needed to develop CuroNZ’s NRP2945 candidate as a potential therapy to protect the nervous system from MS damage...... Read More - http://www.ms-uk.org/emergingtherapies